Intratumoral distribution of 1p loss in oligodendroglial tumors

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 12, 2007, Pages 1118-1123

  Kros, Johan M ^a   Van Der Weiden, Marcel ^a   Zheng, Ping Pin ^a   Hop, Wim C ^a   Van Den Bent, Martin J ^a   Kouwenhoven, Mathilde C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

1p loss; Brain tumor; Fluorescent in situ hybridization (FISH); Heterogeneity; Oligodendroglioma

Indexed keywords

ARTICLE; CHROMOSOME 1Q; CHROMOSOME LOSS; CORRELATION COEFFICIENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; OLIGODENDROGLIOMA; SURVIVAL ANALYSIS;

EID: 37349099475     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e31815c254d     Document Type: Article

References (33)

1. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14
2. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22
3. van den Bent MJ. Diagnosis and management of oligodendroglioma. Semin Oncol 2004;31:645-52
4. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-26
5. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
6. Koschny R, Koschny T, Froster UG, et al. Comparative genomic hybridization in glioma: A meta-analysis of 509 cases. Cancer Genet Cytogenet 2002;135:147-59
7. Kitange G, Misra A, Law M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005;42:68-77
8. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84
9. von Deimling A, Reifenberger G, Kros JM, et al. Oligoastrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC, 2007:63-65
10. Kros JM, Van Eden CG, Stefanko SZ, et al. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 1990;66:1204-12
11. Reifenberger G, Kros JM, Louis DN, et al. Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC, 2007:54-59
12. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-19
13. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 2006;42:2499-503
14. Harkes IC, Elstrodt F, Dinjens WN, et al. Allelotype of 28 human breast cancer cell lines and xenografts. Br J Cancer 2003;89:2289-92
15. French PJ, Swagemakers SM, Nagel JH, et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005;65:11335-44
16. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90
17. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45
18. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602
19. Hatanpaa KJ, Burger PC, Eshleman JR, et al. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 2003;83:419-28
20. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95
21. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10
22. Hartmann C, von Deimling A. Oligodendrogliomas: Impact of molecular genetics on treatment. Neurol India 2005;53:140-48
23. Dong ZQ, Pang JC, Tong CY, et al. Clonality of oligoastrocytomas. Hum Pathol 2002;33:528-35
24. Walker C, du Plessis DG, Joyce KA. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005;57:855-65
25. Kros JM, van Run PR, Alers JC, et al. Spatial variability of genomic aberrations in a large glioblastoma resection specimen. Acta Neuropathol (Berl) 2001;102:103-9
26. Jeuken JW, Sprenger SH, Vermeer H, et al. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: Clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002;96:559-64
27. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996;13:983-94
28. Walker C, du Plessis DG, Joyce KA, et al. Phenotype versus genotype in gliomas displaying inter-or intratumoral histological heterogeneity. Clin Cancer Res 2003;9:4841-51
29. Kim SH, Kim H, Kim TS. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol (Berl) 2005;110:27-38
30. Fuller CE, Wang H, Zhang W, et al. High-throughput molecular profiling of high-grade astrocytomas: The utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol 2002;61:1078-84
31. Perry A, Nobori T, Ru N, et al. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 1997;56:999-1008
32. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45
33. Nishizaki T, Harada K, Kubota H, et al. Chromosome instability in malignant astrocytic tumors detected by fluorescence in situ hybridization. J Neurooncol 2002;56:159-65